Anton Forsberg Morén

Anton Forsberg Morén

Researcher
Visiting address: Akademiska Stråket 1, Bioclinicum, J4-14, 17176 Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 Imaging CF BMIC, 171 77 Stockholm

About me

  • Core Facility Manager of the Brain Molecular Imaging Centre (BMIC) Researcher in the research group of Andrea Varrone working in the imaging field
    with the technique Positron Emission Tomography (PET).

Research

  • My main research is using neuroimaging within neurodegenerative diseases mainly including Alzeimer’s Disease (AD) as well as other neurodegenerative disorders such as Parkinson’s Disease (PD) and Huntington’s Disease (HD). The main method used is Positron Emission Tomography (PET) using various biomarkers for Amyloid, Tau, and radioligands for neuroinflammation, etc.


    My first years in PET research included the world first studies of in vivo amyloid PET imaging in mild cognitive impairment (MC) and longitudinal
    changes of amyloid load in AD. I have after that continued AD research at the Karolinska PET center in Solna including several projects focusing on
    evaluation and application of novel PET radioligands targeting amyloid and neuroinflammatory targets such as the Translocator protein (TSPO) in
    microglia. Besides my focus on AD I have been and currently am involved in many other projects including studies of pathological changes in PD
    investigating the serotonergic and dopaminergic systems and neuroinflammation, as well as developing novel radioligands targeting mutant
    huntingtin in HD. 

    During my 19 year long career within PET research I have become an expert in  data analysis and modelling of PET data in humans as well as non-human primates. As part of my work here at Karolinska Institutet PET center I have also worked extensively with project management of academic projects as well as collaborations with industrial partners. Therefore my involvement and tasks within this application is clearly connected to both my interests in the research fields as well as my expertise in PET data analysis and project management.

Teaching

  • Organizer of the one week long research education course “Positron Emission Tomography Imaging of the CNS. Methodology and clinical applications". 

    Co-organizer of the Master course “Introduction to Brain Imaging in Neuroscience: With a Focus on MRI, PET, EEG and MEG Methods”.

Articles

All other publications

Grants

  • Alzheimer's Association
    1 January 2018
    Background The protein fragment beta-amyloid has long been studied as a key suspect molecule in Alzheimer’s. This fragment tends to accumulate into clumps called plaques, which may hinder nerve cell communication in the brain and lead to brain cell death. Beta-amyloid is produced from its parent molecule, amyloid precursor protein (APP), in a two-stage process. The enzyme Beta-secretase 1 (BACE1) begins the production process for beta-amyloid. Many research teams have studied whether blocking the activity of BACE1 could slow or prevent Alzheimer’s
    these studies have either experienced side effects or are still ongoing. Recent studies suggest that beta-amyloid is present and maybe playing a role in early stage of Alzheimer’s, even before the loss of brain function is pronounced. Future studies, therefore, will need to focus on determining how beta-amyloid production changes during early stages of Alzheimer’s.<br /> Research Plan Using a new imaging brain scan tool, Dr. Anton Forsberg Morén and colleagues plan to determine BACE1 activity in the brains of two types of participants- 1) those who are cognitively unimpaired and 2) in those with mild cognitive impairment (MCI). This information will help assess how BACE1 activity differs in MCI. The researcher’s brain scan technique will feature a special compound (named [18F]PF-06684511), which can attach itself to BACE1 and emit a signal that can help “highlight” BACE1’s activity in the brain scans. The researchers will then assess how BACE1 activity differs in MCI brains compared with the cognitively unimpaired brains.<br /> Impact The study results could shed new light on how beta-amyloid production changes in the early stages of Alzheimer’s. It could also lead to future studies using the special molecule in brain scans. Ultimately, such work could help produce effective therapies for Alzheimer’s. <br />

Employments

  • Researcher, Department of Clinical Neuroscience, Karolinska Institutet, 2018-

Degrees and Education

  • Degree Of Doctor Of Philosophy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2008

News from KI

Events from KI